hotspot -WSS

hotspot

author：leisure time 2025-10-01 02:28:00 - browse：53

David Liu and Jonathan Wosen on the STAT Summit stage. — David Liu (left) with reporter Jonathan Wosen at the 2022 STAT Summit. STAT

David Liu, the Broad Institute biochemist behind two powerful forms of genome editing, is launching a company focused on delivering gene-editing machinery to precise cells and tissues in the body, STAT has learned.

The company, known as Nvelop, already raised a $100 million seed round last year, according to PitchBook. It is being run by Jeff Walsh, a former top executive at Bluebird Bio, and it recently recruited Bluebird’s head of research, Melissa Bonner, according to two people with knowledge of the situation. Bluebird had not previously disclosed Bonner’s departure.

Nvelop is the latest entry in a race among top labs and deep-pocketed investors to solve a delivery problem that has stunted efforts to turn CRISPR and other genetic tools into disease-altering medicines. The goal is to develop a cargo system precise enough to deliver CRISPR or other machinery to cells of a researchers’ choosing, particularly tissues that have been hard to reach with previous approaches, like neurons, muscle, and blood stem cells.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Class action alleges UnitedHealth concealed DOJ probe

entertainment

WSS

As health system earnings go up, health insurance stocks go down

STAT Summit: The economic case for universal basic health care

Brain technologies pose threats that are all too real, experts warn

Warren pushes Witty on UnitedHealth's control over physicians

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

hotspot

hotspot

hotspot

Anesthesiologist group: stop taking Ozempic before surgery

As health system earnings go up, health insurance stocks go down

Drug repurposing or repositioning? The language matters

The effects of a landmark ruling on DNA ownership are becoming clearer

Drug repurposing or repositioning? The language matters

Cassava Sciences’ Alzheimer’s clinical trials should be halted

Moonlake's readout produced a cash windfall. Risks remain

ADCs take center stage as promising cancer treatments

Activists slam private health insurers over coverage restrictions

Is there really a nursing shortage in the U.S.?

entertainment

Class action alleges UnitedHealth concealed DOJ probe

Novel spinal cord stimulator treats paralysis without surgery

Roivant's CEO is a star, but biotech's black hole persists

Smaller biotechs seek to piggyback on weight loss drug boom

BIO to announce reorganization, senior leaders expected to depart

Class action alleges UnitedHealth concealed DOJ probe

hotspot

entertainment

hotspot

Wikipedia